{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:59:10Z","timestamp":1794851950236,"version":"4.9.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Beijing Hospitals Authority Ascent Plan","award":["DFL20221401"],"award-info":[{"award-number":["DFL20221401"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12642-x","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:22:10Z","timestamp":1768987330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of treatment regimens for drug-resistant tuberculosis in different regions: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaonan","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"12642_CR1","unstructured":"World Health Organization. Global tuberculosis report 2024. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024."},{"key":"12642_CR2","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"issue":"1","key":"12642_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","volume":"12","author":"N Salari","year":"2023","unstructured":"Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect Dis Poverty. 2023;12(1):57. https:\/\/doi.org\/10.1186\/s40249-023-01107-x.","journal-title":"Infect Dis Poverty"},{"key":"12642_CR4","unstructured":"World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/B09123"},{"issue":"10","key":"12642_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","volume":"22","author":"M Farhat","year":"2024","unstructured":"Farhat M, Cox H, Ghanem M, Denkinger CM, Rodrigues C, Abd El Aziz MS, et al. Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol. 2024;22(10):617\u201335. https:\/\/doi.org\/10.1038\/s41579-024-01025-1.","journal-title":"Nat Rev Microbiol"},{"key":"12642_CR6","doi-asserted-by":"publisher","unstructured":"Achalu DL, Mohammed FG, Teferi M. Magnitude and impacts of adverse events of injectable containing shorter regimen in programmatic management of multi-drug resistant tuberculosis in ethiopia: a retrospective cohort study. Ther Clin Risk Manag. 2023;19:889\u2013901.https:\/\/doi.org\/10.2147\/TCRM.S423163.","DOI":"10.2147\/TCRM.S423163"},{"issue":"9","key":"12642_CR7","doi-asserted-by":"publisher","first-page":"e0255357","DOI":"10.1371\/journal.pone.0255357","volume":"16","author":"NB Ngoc","year":"2021","unstructured":"Ngoc NB, Vu Dinh H, Thuy NT, Quang DV, Huyen CTT, Hoa NM, et al. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam. PLoS ONE. 2021;16(9):e0255357. https:\/\/doi.org\/10.1371\/journal.pone.0255357.","journal-title":"PLoS ONE"},{"key":"12642_CR8","unstructured":"GA Wells BS, D O\u2019Connell J, Peterson V, Welch M, Losos PT. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2021. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"12642_CR9","unstructured":"Risk of Bias 2 (RoB. 2) tool 2021. Available from: https:\/\/methods.cochrane.org\/risk-bias-2."},{"key":"12642_CR10","unstructured":"ROBINS-I tool. 2017. Available from: https:\/\/methods.cochrane.org\/robins-i."},{"key":"12642_CR11","unstructured":"the Joanna Briggs Institute (JBI). 2017. Available from: https:\/\/jbi.global\/critical-appraisal-tools."},{"issue":"6","key":"12642_CR12","first-page":"1346","volume":"15","author":"P Tabarsi","year":"2009","unstructured":"Tabarsi P, Baghaei P, Hemmati N, Mirsaeidi M, Kazempour M, Mansouri D, et al. Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis. East Mediterr Health J. 2009;15(6):1346\u201350.","journal-title":"East Mediterr Health J"},{"key":"12642_CR13","unstructured":"Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res. 2011;133(5):529\u201334."},{"issue":"2","key":"12642_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3904\/kjim.2011.26.2.153","volume":"26","author":"J Lee","year":"2011","unstructured":"Lee J, Lee CH, Kim DK, Yoon HI, Kim JY, Lee SM, et al. Retrospective comparison of Levofloxacin and Moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med. 2011;26(2):153\u20139. https:\/\/doi.org\/10.3904\/kjim.2011.26.2.153.","journal-title":"Korean J Intern Med"},{"issue":"10","key":"12642_CR15","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","volume":"18","author":"KJ Aung","year":"2014","unstructured":"Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180\u20137. https:\/\/doi.org\/10.5588\/ijtld.14.0100.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"12642_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1313865.","journal-title":"N Engl J Med"},{"key":"12642_CR17","doi-asserted-by":"publisher","first-page":"542DOI","DOI":"10.1186\/1471-2334-14-542","volume":"14","author":"C Modongo","year":"2014","unstructured":"Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, et al. Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. BMC Infect Dis. 2014;14:542DOI. https:\/\/doi.org\/10.1186\/1471-2334-14-542.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"12642_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmi.2014.08.008","volume":"21","author":"JY Chien","year":"2015","unstructured":"Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients with Isoniazid mono-resistant tuberculosis. Clin Microbiol Infect. 2015;21(1):59\u201368. https:\/\/doi.org\/10.1016\/j.cmi.2014.08.008.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"12642_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5588\/ijtld.14.0535","volume":"19","author":"C Kuaban","year":"2015","unstructured":"Kuaban C, Noeske J, Rieder HL, A\u00eft-Khaled N, Abena Foe JL, Tr\u00e9bucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517\u201324. https:\/\/doi.org\/10.5588\/ijtld.14.0535.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"12642_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/civ027","volume":"60","author":"S Tang","year":"2015","unstructured":"Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60(9):1361\u20137. https:\/\/doi.org\/10.1093\/cid\/civ027.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"12642_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","volume":"45","author":"S Tang","year":"2015","unstructured":"Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161\u201370. https:\/\/doi.org\/10.1183\/09031936.00035114.","journal-title":"Eur Respir J"},{"key":"12642_CR22","doi-asserted-by":"publisher","unstructured":"Kang YA, Shim TS, Koh W-J, Lee SH, Lee C-H, Choi JC, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc. 2016;13:364\u201370. https:\/\/doi.org\/10.1513\/AnnalsATS.201510-690BC.","DOI":"10.1513\/AnnalsATS.201510-690BC"},{"issue":"4","key":"12642_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jiph.2015.11.011","volume":"9","author":"SV Patel","year":"2016","unstructured":"Patel SV, Nimavat KB, Alpesh PB, Shukla LK, Shringarpure KS, Mehta KG, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western india: A prospective study. J Infect Public Health. 2016;9(4):478\u201384. https:\/\/doi.org\/10.1016\/j.jiph.2015.11.011.","journal-title":"J Infect Public Health"},{"issue":"1","key":"12642_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5588\/pha.15.0068","volume":"6","author":"NT Phuong","year":"2016","unstructured":"Phuong NT, Nhung NV, Hoa NB, Thuy HT, Takarinda KC, Tayler-Smith K, et al. Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public Health Action. 2016;6(1):25\u201331. https:\/\/doi.org\/10.5588\/pha.15.0068.","journal-title":"Public Health Action"},{"issue":"2","key":"12642_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","volume":"47","author":"AS Pym","year":"2016","unstructured":"Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564\u201374. https:\/\/doi.org\/10.1183\/13993003.00724-2015.","journal-title":"Eur Respir J"},{"issue":"6","key":"12642_CR26","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1183\/13993003.00214-2016","volume":"47","author":"S Tiberi","year":"2016","unstructured":"Tiberi S, Sotgiu G, D\u2019Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, et al. Comparison of effectiveness and safety of imipenem\/clavulanate- versus meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J. 2016;47(6):1758\u201366. https:\/\/doi.org\/10.1183\/13993003.00214-2016.","journal-title":"Eur Respir J"},{"issue":"3","key":"12642_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/tmi.12826","volume":"22","author":"KA Alene","year":"2017","unstructured":"Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2017;22(3):351\u201362. https:\/\/doi.org\/10.1111\/tmi.12826.","journal-title":"Trop Med Int Health"},{"key":"12642_CR28","doi-asserted-by":"publisher","unstructured":"Borisov SE, Dheda K, Enwerem M, Leyet RR, D\u2019Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5). https:\/\/doi.org\/10.1183\/13993003.00387-2017.","DOI":"10.1183\/13993003.00387-2017"},{"key":"12642_CR29","doi-asserted-by":"publisher","unstructured":"Dalcolmo M, Gayoso R, Sotgiu G, D\u2019Ambrosio L, Rocha JL, Borga L, et al. Effectiveness and safety of Clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017;49(3). https:\/\/doi.org\/10.1183\/13993003.02445-2016.","DOI":"10.1183\/13993003.02445-2016"},{"issue":"3","key":"12642_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/ijmy.ijmy_59_17","volume":"6","author":"K Prajapati","year":"2017","unstructured":"Prajapati K, Mishra V, Desai M, Solanki R, Naik P. Treatment outcome of patients having extensively drug-resistant tuberculosis in Gujarat, India. Int J Mycobacteriol. 2017;6(3):289\u201395. https:\/\/doi.org\/10.4103\/ijmy.ijmy_59_17.","journal-title":"Int J Mycobacteriol"},{"issue":"2","key":"12642_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5588\/pha.17.0013","volume":"7","author":"SL Suryawanshi","year":"2017","unstructured":"Suryawanshi SL, Shewade HD, Nagaraja SB, Nair SA, Parmar M. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India. Public Health Action. 2017;7(2):116\u201322. https:\/\/doi.org\/10.5588\/pha.17.0013.","journal-title":"Public Health Action"},{"key":"12642_CR32","doi-asserted-by":"publisher","unstructured":"Thu MK, Kumar AMV, Soe KT, Saw S, Thein S, Mynit Z. High treatment success rate among multidrug-resistant tuberculosis patients in Myanmar, 2012\u20132014: a retrospective cohort study. Trans R Soc Trop Med Hyg. 2017;111:410\u20137. https:\/\/doi.org\/10.1093\/trstmh\/trx074.","DOI":"10.1093\/trstmh\/trx074"},{"key":"12642_CR33","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.12659\/MSM.904682","volume":"23","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, et al. Adverse events associated with treatment of Multidrug-Resistant tuberculosis in china: an ambispective cohort study. Med Sci Monit. 2017;23:2348\u201356. https:\/\/doi.org\/10.12659\/MSM.904682.","journal-title":"Med Sci Monit"},{"key":"12642_CR34","doi-asserted-by":"publisher","unstructured":"Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018;51(5). https:\/\/doi.org\/10.1183\/13993003.00544-2018.","DOI":"10.1183\/13993003.00544-2018"},{"key":"12642_CR35","doi-asserted-by":"publisher","unstructured":"Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, et al. Unacceptable treatment outcomes and associated factors among india\u2019s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised National TB control programme (2007\u20132011): evidence leading to policy enhancement. PLoS ONE. 2018;13(4). https:\/\/doi.org\/10.1371\/journal.pone.0193903.","DOI":"10.1371\/journal.pone.0193903"},{"key":"12642_CR36","doi-asserted-by":"publisher","unstructured":"Wang Q, Pang Y, Jing W, Liu Y, Wang N, Yin H, et al. Clofazimine for treatment of extensively Drug-Resistant pulmonary tuberculosis in China. Antimicrob Agents Chemother. 2018;62(4). https:\/\/doi.org\/10.1128\/aac.02149-17.","DOI":"10.1128\/aac.02149-17"},{"issue":"4","key":"12642_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jinf.2017.12.017","volume":"76","author":"C Xu","year":"2018","unstructured":"Xu C, Pang Y, Li R, Ruan Y, Wang L, Chen M, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect. 2018;76(4):348\u201353. https:\/\/doi.org\/10.1016\/j.jinf.2017.12.017.","journal-title":"J Infect"},{"key":"12642_CR38","doi-asserted-by":"publisher","unstructured":"Ali MH, Alrasheedy AA, Kibuule D, Godman B, Hassali MA, Ali HMH. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev Anti Infect Ther. 2019;17(11):927\u201337. https:\/\/doi.org\/10.1080\/14787210.2019.1689818.","DOI":"10.1080\/14787210.2019.1689818"},{"issue":"3","key":"12642_CR39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4269\/ajtmh.19-0175","volume":"101","author":"ML Aznar","year":"2019","unstructured":"Aznar ML, Rando Segura A, Moreno MM, Espasa M, Sulleiro E, Bocanegra C, et al. Treatment outcomes and adverse events from a standardized Multidrug-Resistant tuberculosis regimen in a rural setting in Angola. Am J Trop Med Hyg. 2019;101(3):502\u20139. https:\/\/doi.org\/10.4269\/ajtmh.19-0175.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"12642_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cmi.2018.07.012","volume":"25","author":"H Duan","year":"2019","unstructured":"Duan H, Chen X, Li Z, Pang Y, Jing W, Liu P, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2019;25(2):190\u20135. https:\/\/doi.org\/10.1016\/j.cmi.2018.07.012.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"12642_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12879-019-3931-5","volume":"19","author":"M El Hamdouni","year":"2019","unstructured":"El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in morocco: multi-centric prospective study. BMC Infect Dis. 2019;19(1):316. https:\/\/doi.org\/10.1186\/s12879-019-3931-5.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"12642_CR42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jiph.2019.04.009","volume":"12","author":"I Khan","year":"2019","unstructured":"Khan I, Ahmad N, Khan S, Muhammad S, Ahmad Khan S, Ahmad I, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan Province of Pakistan. J Infect Public Health. 2019;12(6):809\u201315. https:\/\/doi.org\/10.1016\/j.jiph.2019.04.009.","journal-title":"J Infect Public Health"},{"key":"12642_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/IDR.S195555","volume":"12","author":"Y Li","year":"2019","unstructured":"Li Y, Wang F, Wu L, Zhu M, He G, Chen X, et al. Cycloserine for treatment of multidrug-resistant tuberculosis: A retrospective cohort study in China. Infect Drug Resist. 2019;12:721\u201331. https:\/\/doi.org\/10.2147\/IDR.S195555.","journal-title":"Infect Drug Resist"},{"issue":"13","key":"12642_CR44","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn AJ, Phillips PPJ, Meredith SK, Chiang C-Y, Conradie F, Dalai D, et al. A trial of a shorter regimen for Rifampin-Resistant tuberculosis. N Engl J Med. 2019;380(13):1201\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1811867.","journal-title":"N Engl J Med"},{"key":"12642_CR45","doi-asserted-by":"publisher","unstructured":"Shibeshi W, Sheth AN, Admasu A, Berha AB, Negash Z, Yimer G. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in ethiopia: a retrospective cohort study. BMC Pharmacol Toxicol. 2019;20. https:\/\/doi.org\/10.1186\/s40360-019-0313-y.","DOI":"10.1186\/s40360-019-0313-y"},{"issue":"5","key":"12642_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4103\/lungindia.lungindia_475_18","volume":"36","author":"A Singh","year":"2019","unstructured":"Singh A, Prasad R, Kushwaha RAS, Srivastava R, Giridhar BH, Balasubramanian V, et al. Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years\u2019 experience. LUNG INDIA. 2019;36(5):384\u201392. https:\/\/doi.org\/10.4103\/lungindia.lungindia_475_18.","journal-title":"LUNG INDIA"},{"issue":"3","key":"12642_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s2213-2600(18)30426-0","volume":"7","author":"F von Groote-Bidlingmaier","year":"2019","unstructured":"von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr., Ticona E, Segura P, et al. Efficacy and safety of Delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249\u201359. https:\/\/doi.org\/10.1016\/s2213-2600(18)30426-0.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"12642_CR48","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/cid\/ciz039","volume":"69","author":"KF Walsh","year":"2019","unstructured":"Walsh KF, Vilbrun SC, Souroutzidis A, Delva S, Joissaint G, Mathurin L, et al. Improved outcomes with High-dose Isoniazid in Multidrug-resistant tuberculosis treatment in Haiti. Clin Infect Dis. 2019;69(4):717\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz039.","journal-title":"Clin Infect Dis"},{"key":"12642_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2147\/IDR.S194484","volume":"12","author":"J Wang","year":"2019","unstructured":"Wang J, Pang Y, Jing W, Chen W, Guo R, Han X, et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect DRUG Resist. 2019;12:763\u201370. https:\/\/doi.org\/10.2147\/IDR.S194484.","journal-title":"Infect DRUG Resist"},{"key":"12642_CR50","doi-asserted-by":"publisher","unstructured":"Anh LTN, Ramaswamy AMVK, Htun G, Thanh Hoang Thi T, Hoai Nguyen T. High levels of treatment success and zero relapse in Multidrug-Resistant tuberculosis patients receiving a Levofloxacin-Based shorter treatment regimen in Vietnam. Trop Med Infect Dis. 2020;5(1). https:\/\/doi.org\/10.3390\/tropicalmed5010043.","DOI":"10.3390\/tropicalmed5010043"},{"issue":"10","key":"12642_CR51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly Drug-Resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"N Engl J Med"},{"issue":"4","key":"12642_CR52","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/cid\/ciz915","volume":"71","author":"Y Du","year":"2020","unstructured":"Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H, et al. Treatment outcome of a shorter regimen containing Clofazimine for Multidrug-resistant tuberculosis: A randomized control trial in China. Clin Infect Dis. 2020;71(4):1047\u201354. https:\/\/doi.org\/10.1093\/cid\/ciz915.","journal-title":"Clin Infect Dis"},{"key":"12642_CR53","doi-asserted-by":"publisher","unstructured":"Ghimire S, Karki S, Maharjan B, Kosterink JGW, Touw DJ, van der Werf TS, et al. Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study. BMJ Open Respir Res. 2020;7(1). https:\/\/doi.org\/10.1136\/bmjresp-2020-000606.","DOI":"10.1136\/bmjresp-2020-000606"},{"key":"12642_CR54","doi-asserted-by":"publisher","unstructured":"Hassane-Harouna S, Cherif G-F, Ortuno-Gutierrez N, Cisse D, Camara LM, Diallo BD, et al. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in guinea: A retrospective cohort study. PLoS ONE. 2020;15(8). https:\/\/doi.org\/10.1371\/journal.pone.0237355.","DOI":"10.1371\/journal.pone.0237355"},{"issue":"9","key":"12642_CR55","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","volume":"71","author":"RR Kempker","year":"2020","unstructured":"Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical outcomes among patients with Drug-resistant tuberculosis receiving Bedaquiline- or Delamanid-Containing regimens. Clin Infect Dis. 2020;71(9):2336\u201344. https:\/\/doi.org\/10.1093\/cid\/ciz1107.","journal-title":"Clin Infect Dis"},{"key":"12642_CR56","doi-asserted-by":"publisher","unstructured":"Matambo R, Takarinda KC, Thekkur P, Sandy C, Mharakurwa S, Makoni T, et al. Treatment outcomes of multi drug resistant and rifampicin resistant tuberculosis in zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015. PLoS ONE. 2020;15(4). https:\/\/doi.org\/10.1371\/journal.pone.0230848.","DOI":"10.1371\/journal.pone.0230848"},{"issue":"4","key":"12642_CR57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.5588\/ijtld.19.0444","volume":"24","author":"L Mikiashvili","year":"2020","unstructured":"Mikiashvili L, Kipiani M, Schechter MC, Avaliani Z, Kiria N, Kempker RR. Linezolid use for drug-resistant tuberculosis in georgia: A retrospective cohort study. Int J Tuberculosis Lung Disease. 2020;24(4):436\u201343. https:\/\/doi.org\/10.5588\/ijtld.19.0444.","journal-title":"Int J Tuberculosis Lung Disease"},{"key":"12642_CR58","doi-asserted-by":"publisher","unstructured":"Olayanju O, Esmail A, Limberis J, Dheda K. A regimen containing bedaquiline and Delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J. 2020;55(1). https:\/\/doi.org\/10.1183\/13993003.01181-2019.","DOI":"10.1183\/13993003.01181-2019"},{"key":"12642_CR59","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jgar.2020.07.012","volume":"22","author":"Y Shao","year":"2020","unstructured":"Shao Y, Li Y, Song H, Li G, Li Y, Zhu L, et al. A retrospective cohort study of Isoniazid-resistant tuberculosis treatment outcomes and Isoniazid resistance-associated mutations in Eastern China from 2013 to 2018. J Glob Antimicrob Resist. 2020;22:847\u201353. https:\/\/doi.org\/10.1016\/j.jgar.2020.07.012.","journal-title":"J Glob Antimicrob Resist"},{"key":"12642_CR60","doi-asserted-by":"publisher","first-page":"100268DOI","DOI":"10.1016\/j.eclinm.2020.100268","volume":"20","author":"V Schw\u0153bel","year":"2020","unstructured":"Schw\u0153bel V, Tr\u00e9bucq A, Kashongwe Z, Bakayoko AS, Kuaban C, Noeske J, et al. Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries. EClinicalMedicine. 2020;20:100268DOI. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100268.","journal-title":"EClinicalMedicine"},{"key":"12642_CR61","doi-asserted-by":"publisher","first-page":"105844DOI","DOI":"10.1016\/j.rmed.2019.105844","volume":"161","author":"A Piubello","year":"2020","unstructured":"Piubello A, Souleymane MB, Hassane-Harouna S, Yacouba A, Lempens P, Assao-Neino MM, et al. Management of multidrug-resistant tuberculosis with shorter treatment regimen in niger: nationwide programmatic achievements. Respir Med. 2020;161:105844DOI. https:\/\/doi.org\/10.1016\/j.rmed.2019.105844.","journal-title":"Respir Med"},{"key":"12642_CR62","doi-asserted-by":"publisher","unstructured":"Auchynka V, Kumar AMV, Hurevich H, Sereda Y, Solodovnikova V, Katovich D, et al. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrugresistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18. Monaldi Arch Chest Dis. 2021;91(1). https:\/\/doi.org\/10.4081\/MONALDI.2021.1647.","DOI":"10.4081\/MONALDI.2021.1647"},{"issue":"11","key":"12642_CR63","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/cid\/ciab335","volume":"73","author":"JCM Brust","year":"2021","unstructured":"Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, et al. Effectiveness and cardiac safety of Bedaquiline-Based therapy for Drug-Resistant tuberculosis: A prospective cohort study. Clin Infect Dis. 2021;73(11):2083\u201392. https:\/\/doi.org\/10.1093\/cid\/ciab335.","journal-title":"Clin Infect Dis"},{"key":"12642_CR64","doi-asserted-by":"publisher","unstructured":"Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reimann M, et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2021;57(6). https:\/\/doi.org\/10.1183\/13993003.02544-2020.","DOI":"10.1183\/13993003.02544-2020"},{"issue":"9","key":"12642_CR65","doi-asserted-by":"publisher","first-page":"E3496","DOI":"10.1093\/cid\/ciaa1577","volume":"73","author":"M Das","year":"2021","unstructured":"Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F, Meneguim AC, et al. One step forward: successful End-of-Treatment outcomes of patients with Drug-Resistant tuberculosis who received concomitant bedaquiline and Delamanid in Mumbai, India. Clin Infect Dis. 2021;73(9):E3496\u2013504. https:\/\/doi.org\/10.1093\/cid\/ciaa1577.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12642_CR66","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/cid\/ciab304","volume":"73","author":"H Hwang","year":"2021","unstructured":"Hwang H, Kang H, Kwon Y-S, Jeon D, Shim TS, Yim J-J. Outcomes of Multidrug-Resistant tuberculosis treated with bedaquiline or Delamanid. Clin Infect Dis. 2021;73(8):1362\u20139. https:\/\/doi.org\/10.1093\/cid\/ciab304.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"12642_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5588\/pha.21.0041","volume":"11","author":"S Koirala","year":"2021","unstructured":"Koirala S, Shah NP, Pyakurel P, Khanal M, Rajbhandari SK, Pun T, et al. High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal. Public Health Action. 2021;11(Suppl 1):38\u201345. https:\/\/doi.org\/10.5588\/pha.21.0041.","journal-title":"Public Health Action"},{"key":"12642_CR68","doi-asserted-by":"publisher","first-page":"229DOI","DOI":"10.11604\/pamj.2021.38.229.28317","volume":"38","author":"A Kuaban","year":"2021","unstructured":"Kuaban A, Balkissou AD, Ekongolo MCE, Nsounfon AW, Pefura-Yone EW, Kuaban C. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaound\u00e9, Cameroon. Pan Afr Med J. 2021;38:229DOI. https:\/\/doi.org\/10.11604\/pamj.2021.38.229.28317.","journal-title":"Pan Afr Med J"},{"key":"12642_CR69","doi-asserted-by":"publisher","unstructured":"Sidamo T, Shibeshi W, Yimer G, Aklillu E, Engidawork E. Explorative analysis of treatment outcomes of levofloxacin- and moxifloxacin-based regimens and outcome predictors in Ethiopian MDR-TB patients: A prospective observational cohort Study. Infect Drug Resist. 2021;14:5473\u201389.https:\/\/doi.org\/10.2147\/IDR.S342964.","DOI":"10.2147\/IDR.S342964"},{"issue":"6","key":"12642_CR70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5588\/ijtld.21.0035","volume":"25","author":"S Oelofse","year":"2021","unstructured":"Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, Ngubane N, et al. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts. Int J Tuberc Lung Dis. 2021;25(6):453\u201360. https:\/\/doi.org\/10.5588\/ijtld.21.0035.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12642_CR71","doi-asserted-by":"publisher","unstructured":"Sayfutdinov Z, Kumar A, Nabirova D, Gadoev J, Turaev L, Sultanov S, et al. Treatment outcomes of Isoniazid-Resistant (Rifampicin Susceptible) tuberculosis patients in Uzbekistan, 2017\u20132018. Int J Environ Res Public Health. 2021;18(6). https:\/\/doi.org\/10.3390\/ijerph18062965.","DOI":"10.3390\/ijerph18062965"},{"key":"12642_CR72","doi-asserted-by":"publisher","unstructured":"Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java indonesia: A retrospective cohort study. PLoS ONE. 2021;16(2 February). https:\/\/doi.org\/10.1371\/journal.pone.0246284.","DOI":"10.1371\/journal.pone.0246284"},{"key":"12642_CR73","doi-asserted-by":"publisher","unstructured":"Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, et al. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. Eur Respir J. 2021;57(1). https:\/\/doi.org\/10.1183\/13993003.02250-2020.","DOI":"10.1183\/13993003.02250-2020"},{"issue":"1","key":"12642_CR74","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1186\/s12879-021-06553-2","volume":"21","author":"W Sun","year":"2021","unstructured":"Sun W, Wu Z, Zhou Y, Xia F, Tang Q, Wang J, et al. A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China. BMC Infect Dis. 2021;21(1):834. https:\/\/doi.org\/10.1186\/s12879-021-06553-2.","journal-title":"BMC Infect Dis"},{"key":"12642_CR75","doi-asserted-by":"publisher","unstructured":"Tola H, Holakouie-Naieni K, Mansournia MA, Yaseri M, Gamtesa DF, Tesfaye E, et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in ethiopia: a 10-year retrospective cohort study. BMJ OPEN. 2021;11(8). https:\/\/doi.org\/10.1136\/bmjopen-2020-040862.","DOI":"10.1136\/bmjopen-2020-040862"},{"issue":"9","key":"12642_CR76","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.3855\/jidc.13757","volume":"15","author":"E Zhdanova","year":"2021","unstructured":"Zhdanova E, Goncharova O, Davtyan H, Alaverdyan S, Sargsyan A, Harries AD, et al. 9\u201312 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. J Infect DEVELOPING Ctries. 2021;15(9):S66\u201374. https:\/\/doi.org\/10.3855\/jidc.13757.","journal-title":"J Infect DEVELOPING Ctries"},{"issue":"10","key":"12642_CR77","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","volume":"205","author":"A Esmail","year":"2022","unstructured":"Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, et al. An All-Oral 6-Month regimen for Multidrug-Resistant tuberculosis: A Multicenter, randomized controlled clinical trial (the next Study). Am J Respir Crit Care Med. 2022;205(10):1214\u201327. https:\/\/doi.org\/10.1164\/rccm.202107-1779OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10366","key":"12642_CR78","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022;400(10366):1858\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(22)02078-5.","journal-title":"Lancet"},{"issue":"3","key":"12642_CR79","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/ijmy.ijmy_86_22","volume":"11","author":"HT Indarti","year":"2022","unstructured":"Indarti HT, Kristin E, Soedarsono S, Endarti D. Treatment outcomes of Multidrug-Resistant tuberculosis patients in East Java, indonesia: A retrospective cohort analysis. Int J Mycobacteriology. 2022;11(3):261\u20137. https:\/\/doi.org\/10.4103\/ijmy.ijmy_86_22.","journal-title":"Int J Mycobacteriology"},{"key":"12642_CR80","doi-asserted-by":"publisher","unstructured":"Min J, Kim HW, Kang JY, Kim SK, Kim JW, Kim YH, et al. Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study. PLoS ONE. 2022;17(8). https:\/\/doi.org\/10.1371\/journal.pone.0273263.","DOI":"10.1371\/journal.pone.0273263"},{"issue":"10362","key":"12642_CR81","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"J Mok","year":"2022","unstructured":"Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo K-W, et al. 9 months of delamanid, linezolid, levofloxacin, and Pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522\u201330.","journal-title":"Lancet"},{"issue":"7","key":"12642_CR82","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","volume":"22","author":"N Ndjeka","year":"2022","unstructured":"Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South africa: a retrospective cohort study. LANCET Infect Dis. 2022;22(7):1042\u201351. https:\/\/doi.org\/10.1016\/S1473-3099(21)00811-2.","journal-title":"LANCET Infect Dis"},{"key":"12642_CR83","doi-asserted-by":"publisher","unstructured":"Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, Santoso P, et al. Factors associated with treatment outcome of MDR\/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. PLoS ONE. 2022;17(1). https:\/\/doi.org\/10.1371\/journal.pone.0263304.","DOI":"10.1371\/journal.pone.0263304"},{"key":"12642_CR84","doi-asserted-by":"publisher","unstructured":"Wahid A, Ghafoor A, Khan AW, Al-Worafi YM, Latif A, Shahwani NA, et al. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.973713.","DOI":"10.3389\/fphar.2022.973713"},{"issue":"1","key":"12642_CR85","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12879-022-07693-9","volume":"22","author":"SJ Zhang","year":"2022","unstructured":"Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, Li YP, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR\/MDR\/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1):715. https:\/\/doi.org\/10.1186\/s12879-022-07693-9.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"12642_CR86","doi-asserted-by":"publisher","first-page":"761","DOI":"10.55730\/1300-0144.5639","volume":"53","author":"AF Aslan","year":"2023","unstructured":"Aslan AF, Ortak\u00f6yl\u00fc MG, Ba\u011fc\u0131 BA, Toprak S. Evaluation of treatment regimens and long-term clinical outcomes in patients with isoniazid-resistant pulmonary tuberculosis: a 5-year follow-up. Turk J Med Sci. 2023;53(3):761\u201370. https:\/\/doi.org\/10.55730\/1300-0144.5639.","journal-title":"Turk J Med Sci"},{"key":"12642_CR87","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijid.2022.11.007","volume":"126","author":"TMP Nguyen","year":"2023","unstructured":"Nguyen TMP, Le THM, Merle CSC, Pedrazzoli D, Nguyen NL, Decroo T, et al. Effectiveness and safety of bedaquiline-based, modified all-oral 9\u201311-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam. Int J Infect Dis. 2023;126:148\u201354. https:\/\/doi.org\/10.1016\/j.ijid.2022.11.007.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"12642_CR88","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/inthealth\/ihac016","volume":"15","author":"MB Souleymane","year":"2023","unstructured":"Souleymane MB, Decroo T, Mamadou S, Soumana A, Lawan IM, Gagara-Issoufou A, et al. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. Int HEALTH. 2023;15(3):258\u201364. https:\/\/doi.org\/10.1093\/inthealth\/ihac016.","journal-title":"Int HEALTH"},{"issue":"1","key":"12642_CR89","doi-asserted-by":"publisher","first-page":"300060522114841","DOI":"10.1177\/03000605221148416","volume":"51","author":"G Yao","year":"2023","unstructured":"Yao G, Zhu M, Nie Q, Chen N, Tu S, Zhou Y, et al. Improved outcomes following addition of bedaquiline and Clofazimine to a treatment regimen for multidrug-resistant tuberculosis. J Int Med Res. 2023;51(1):3000605221148416. https:\/\/doi.org\/10.1177\/03000605221148416.","journal-title":"J Int Med Res"},{"key":"12642_CR90","doi-asserted-by":"publisher","unstructured":"Achalu DL, Kiltu AB, Teferi M, Mohammed FG, Workneh BD, Beyene KA, et al. Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in ethiopia: a retrospective cohort study. BMC Infect Dis. 2024;24(1). https:\/\/doi.org\/10.1186\/s12879-024-09745-8.","DOI":"10.1186\/s12879-024-09745-8"},{"issue":"1","key":"12642_CR91","doi-asserted-by":"publisher","first-page":"16247","DOI":"10.1038\/s41598-024-65063-8","volume":"14","author":"M Afifi","year":"2024","unstructured":"Afifi M, Amin W, Helal D, Ashmawy R, El-Maradny YA, Khalifa N, et al. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt. Sci Rep. 2024;14(1):16247. https:\/\/doi.org\/10.1038\/s41598-024-65063-8.","journal-title":"Sci Rep"},{"issue":"1","key":"12642_CR92","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/inthealth\/ihad023","volume":"16","author":"MO Fadeyi","year":"2024","unstructured":"Fadeyi MO, Decroo T, Ortu\u00f1o-Guti\u00e9rrez N, Ahmed B, Jinadu A, El-Tayeb O, et al. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria. Int Health. 2024;16(1):123\u20135. https:\/\/doi.org\/10.1093\/inthealth\/ihad023.","journal-title":"Int Health"},{"key":"12642_CR93","doi-asserted-by":"publisher","unstructured":"Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, Vittozzi P, et al. Safety and effectiveness of BPaL-based regimens to treat multidrug-resistant TB: first experience of an Italian tuberculosis referral hospital. Antibiot (Basel). 2024;14(1). https:\/\/doi.org\/10.3390\/antibiotics14010007.","DOI":"10.3390\/antibiotics14010007"},{"key":"12642_CR94","doi-asserted-by":"publisher","unstructured":"Khan S, Silsarma A, Mahajan R, Khan S, Davuluri P, Sutar N, et al. Treatment outcomes among patients with Isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study. J Clin Tuberculosis Other Mycobact Dis. 2024;37. https:\/\/doi.org\/10.1016\/j.jctube.2024.100481.","DOI":"10.1016\/j.jctube.2024.100481"},{"key":"12642_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106291:106291","author":"J Martinez-Camprecios","year":"2024","unstructured":"Martinez-Camprecios J, Aznar ML, Zacarias A, Teran R, Nindia A, Espinosa-Pereiro J, et al. A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis. J Infect. 2024. https:\/\/doi.org\/10.1016\/j.jinf.2024.106291:106291-.","journal-title":"J Infect"},{"issue":"6","key":"12642_CR96","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/cid\/ciae145","volume":"78","author":"H Morgan","year":"2024","unstructured":"Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, Nguyen LN, et al. Treatment of Multidrug-resistant or Rifampicin-resistant tuberculosis with an All-oral 9-month regimen containing linezolid or ethionamide in South africa: A retrospective cohort study. Clin Infect Dis. 2024;78(6):1698\u2013706. https:\/\/doi.org\/10.1093\/cid\/ciae145.","journal-title":"Clin Infect Dis"},{"key":"12642_CR97","doi-asserted-by":"publisher","unstructured":"Myrzaliev B, Ahmatov M, Duishekeeva A, Kulzhabaeva A, Kadyrov A, Toktogonova A, et al. Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan. J Clin Tuberculosis Other Mycobact Dis. 2024;36. https:\/\/doi.org\/10.1016\/j.jctube.2024.100472.","DOI":"10.1016\/j.jctube.2024.100472"},{"issue":"2","key":"12642_CR98","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"B-T Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. LANCET RESPIRATORY Med. 2024;12(2):117\u201328. https:\/\/doi.org\/10.1016\/S2213-2600(23)00389-2.","journal-title":"LANCET RESPIRATORY Med"},{"issue":"4","key":"12642_CR99","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/cid\/ciae305","volume":"79","author":"M Rashitov","year":"2024","unstructured":"Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, Eshmetov G, et al. Safety and effectiveness of 3 novel All-Oral shortened regimens for Rifampicin- or Multidrug-Resistant tuberculosis in Kazakhstan. Clin Infect Dis. 2024;79(4):1046\u201353. https:\/\/doi.org\/10.1093\/cid\/ciae305.","journal-title":"Clin Infect Dis"},{"key":"12642_CR100","doi-asserted-by":"publisher","unstructured":"Santos AP, Benace CJ Jr, de Medeiros Leung JA, Kritski AL, de Queiroz Mello FC. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil \u2013 a real-world evidence study using a retrospective design. BMC Infect Dis. 2024;24(1). https:\/\/doi.org\/10.1186\/s12879-024-09993-8.","DOI":"10.1186\/s12879-024-09993-8"},{"key":"12642_CR101","doi-asserted-by":"publisher","unstructured":"Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, et al. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China. BMC Med. 2024;22(1). https:\/\/doi.org\/10.1186\/s12916-024-03633-3.","DOI":"10.1186\/s12916-024-03633-3"},{"issue":"5","key":"12642_CR102","doi-asserted-by":"publisher","first-page":"284","DOI":"10.5588\/ijtldopen.24.0524","volume":"2","author":"E Burhan","year":"2025","unstructured":"Burhan E, Sugiharto J, Soemarno M, Juan A, Runtu Y, Yuvensia A, et al. Treatment success rate and time to culture conversion under a prospective BPaL cohort study. IJTLD Open. 2025;2(5):284\u201390. https:\/\/doi.org\/10.5588\/ijtldopen.24.0524.","journal-title":"IJTLD Open"},{"issue":"5","key":"12642_CR103","doi-asserted-by":"publisher","first-page":"e0003983","DOI":"10.1371\/journal.pgph.0003983","volume":"5","author":"V Fardhdiani","year":"2025","unstructured":"Fardhdiani V, Trush O, Lytvynenko N, Pylypchuk S, Terleeva Y, Malakyan K, et al. End of treatment and 12-month post-treatment outcomes in patients treated with all-oral regimens for rifampicin-resistant tuberculosis in ukraine: a prospective cohort study. PLOS Glob Public Health. 2025;5(5):e0003983. https:\/\/doi.org\/10.1371\/journal.pgph.0003983.","journal-title":"PLOS Glob Public Health"},{"issue":"2","key":"12642_CR104","doi-asserted-by":"publisher","first-page":"ofaf020","DOI":"10.1093\/ofid\/ofaf020","volume":"12","author":"W Jing","year":"2025","unstructured":"Jing W, Wang Q, Wang J, Ma L, Huang M, Wang J, et al. New All-Oral Short-term regimen for Multidrug-Resistant tuberculosis: A Semi-randomized controlled trial conducted in China. Open Forum Infect Dis. 2025;12(2):ofaf020. https:\/\/doi.org\/10.1093\/ofid\/ofaf020.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"12642_CR105","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12879-024-10417-w","volume":"25","author":"M Rodr\u00edguez","year":"2025","unstructured":"Rodr\u00edguez M, Bustos YC, Encarnaci\u00f3n M, Mu\u00f1oz E, De Los Santos S, S\u00e1nchez I, et al. Evaluation of a modified short all oral treatment regimen for rifampicin-multidrug resistant tuberculosis in Dominican Republic. BMC Infect Dis. 2025;25(1):196. https:\/\/doi.org\/10.1186\/s12879-024-10417-w.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"12642_CR106","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.21276\/SSR-IIJLS.2025.11.1.31","volume":"11","author":"A Shukla","year":"2025","unstructured":"Shukla A, Badal A, Ansari S. Study on the effectiveness and safety of linezolid dose reduction in Multidrug-Resistant tuberculosis. SSR Inst Int J Life Sci. 2025;11(1):6822\u201332. https:\/\/doi.org\/10.21276\/SSR-IIJLS.2025.11.1.31.","journal-title":"SSR Inst Int J Life Sci"},{"key":"12642_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf035","author":"A Sinha","year":"2025","unstructured":"Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, Yatskevich N, et al. The effectiveness and safety of Bedaquiline, Pretomanid, and linezolid (BPaL)-Based regimens for Rifampicin-Resistant tuberculosis in Non-Trial Settings-A prospective cohort study in Belarus and Uzbekistan. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf035.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12642_CR108","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5588\/ijtld.18.0866","volume":"23","author":"V Cox","year":"2019","unstructured":"Cox V, Cox H, Pai M, Stillo J, Citro B, Brigden G. Health care gaps in the global burden of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(2):125\u201335. https:\/\/doi.org\/10.5588\/ijtld.18.0866.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"12642_CR109","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-024-03633-3","volume":"22","author":"Y Song","year":"2024","unstructured":"Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, et al. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China. BMC Med. 2024;22(1):401. https:\/\/doi.org\/10.1186\/s12916-024-03633-3.","journal-title":"BMC Med"},{"key":"12642_CR110","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae601","author":"U Khan","year":"2024","unstructured":"Khan U, Rich M, Franke M, Lachenal N, Ahmed S, Bekele A, et al. The frequency and incidence of QT prolongation with extended use of bedaquiline or Delamanid in a Large, Multi-Country MDR\/RR-TB cohort. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae601.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"12642_CR111","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5588\/pha.24.0041","volume":"14","author":"M Boga","year":"2024","unstructured":"Boga M, Marukutira T, Murray A, Chan GG, Huang GK. Tolerability of linezolid in patients with drug-resistant TB in Daru, Western Province, PNG. Public Health Action. 2024;14(4):158\u201363. https:\/\/doi.org\/10.5588\/pha.24.0041.","journal-title":"Public Health Action"},{"issue":"6","key":"12642_CR112","doi-asserted-by":"publisher","first-page":"e14230","DOI":"10.1111\/jep.14230","volume":"31","author":"SI Shah","year":"2025","unstructured":"Shah SI, Ghafoor A, Rahman SU, Abidullah, Ahmad N, Al-Qaaneh AM, et al. Incidence, types and predictors of adverse events and their impact on treatment outcomes in multidrug\/rifampicin resistant tuberculosis patients receiving all oral treatment regimens. J Eval Clin Pract. 2025;31(6):e14230. https:\/\/doi.org\/10.1111\/jep.14230.","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"12642_CR113","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","volume":"23","author":"S Wu","year":"2016","unstructured":"Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events associated with the treatment of Multidrug-Resistant tuberculosis: A systematic review and Meta-analysis. Am J Ther. 2016;23(2):e521\u201330. https:\/\/doi.org\/10.1097\/01.mjt.0000433951.09030.5a.","journal-title":"Am J Ther"},{"issue":"5","key":"12642_CR114","doi-asserted-by":"publisher","first-page":"e63057","DOI":"10.1371\/journal.pone.0063057","volume":"8","author":"K Shean","year":"2013","unstructured":"Shean K, Streicher E, Pieterson E, Symons G, van Zyl Smit R, Theron G, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS ONE. 2013;8(5):e63057. https:\/\/doi.org\/10.1371\/journal.pone.0063057.","journal-title":"PLoS ONE"},{"issue":"12","key":"12642_CR115","doi-asserted-by":"publisher","first-page":"e82943","DOI":"10.1371\/journal.pone.0082943","volume":"8","author":"S Tang","year":"2013","unstructured":"Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in china: retrospective multi-center investigation. PLoS ONE. 2013;8(12):e82943. https:\/\/doi.org\/10.1371\/journal.pone.0082943.","journal-title":"PLoS ONE"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12642-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12642-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12642-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:52:42Z","timestamp":1771242762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12642-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12642"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12642-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"361"}}